Clinical trial
Safety and Tolerability Study of Larazotide Acetate in Celiac Disease Subjects
NCT00362856 · 9 Meters Biopharma, Inc., Industry · Completed
Key facts
| NCT number | NCT00362856 |
|---|---|
| Title | Safety and Tolerability Study of Larazotide Acetate in Celiac Disease Subjects |
| Official title | A Phase 2a, Randomized, Double-Blind, Placebo Controlled, Dose Ranging, Multicenter Study to Determine the Safety, Tolerance, and Efficacy of Larazotide Acetate (AT-1001) in Celiac Disease Subjects During Gluten Challenge. |
| Lead sponsor | 9 Meters Biopharma, Inc., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Celiac Disease |
| Intervention type | Drug |
| Interventions | larazotide acetate, Placebo |
| Enrollment | 80 |
| Start date | Sep 13, 2006 |
| Primary completion | Mar 6, 2007 |
| Completion | Mar 6, 2007 |
| First posted | Aug 10, 2006 |
| Last update posted | Sep 12, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: